Ceva signs deal to use Touchlight’s dbDNA technology in animal healthCeva signs deal to use Touchlight’s dbDNA technology in animal health

Ceva and Touchlight initiate long-term collaboration to develop and manufacture broad range of new dbDNA vaccines and therapeutics.

Industry Release

January 16, 2025

2 Min Read

Ceva Animal Health, global animal health company, announced it has been granted the rights to develop and manufacture future products using Touchlight’s doggybone DNA (dbDNA) technology across the animal health field.

The partnership brings together the leading development and commercialization capability of Ceva with Touchlight’s best-in-class dbDNA technology, which enables rapid, high-purity enzymatic DNA production and eliminates antibiotic resistance genes.

Under the stewardship of Dr. Ian Thompson, a global leader in vaccines, Ceva and Touchlight will pursue a broad-ranging development program to bring innovative DNA vaccine products to market for animal health.

While the financial terms of the deal remain undisclosed, the agreement includes an upfront payment, development milestones and royalties on sales of commercialized products.

Stonehaven Transactions acted as strategic adviser to Touchlight in relation to the deal, and Arnold & Porter acted as legal adviser. Ceva was assisted by BP Collins and Ernst & Young.

Ceva chairman and chief executive officer Marc Prikazsky remarked, “This is an exciting technology that will complement very well our innovation in nucleic acid vaccines pipeline. Touchlight’s unique expertise in synthetic DNA and protein designs, together with Ceva’s leadership in development and manufacturing of animal vaccines – being the first company to have launched an RNA vaccine for avian flu – will support the development of effective novel technology vaccines  that are so much needed by the industry.”

Related:HPAI not only factor contributing to higher egg prices

Touchlight founder and executive chair Jonny Ohlson said, “This deal is the product of an extremely successful collaboration between Touchlight and Stonehaven, and in Ceva we have found a partner with the ambition, entrepreneurialism and insight required to take dbDNA products forward within animal health. We are excited that we can deploy our industry-leading dbDNA technology in such a broad-ranging program.”

Ceva Animal Health is the fifth-largest global animal health company. Led by experienced veterinarians, its mission is to provide innovative health solutions for all animals to ensure the highest level of care and well-being. Ceva’s portfolio includes preventive medicine such as vaccines, pharmaceutical and animal welfare products for farm and companion animals, as well as equipment and services.

Touchlight is a privately owned, innovation-driven contract development and manufacturing organization based in London, U.K., focused on the provision of DNA services and manufacture of enzymatically produced dbDNA to enable the development of genetic medicines. Touchlight’s dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences. Its revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity not currently possible.

Related:Cargill moves to take full control of SJC Bionergia

The company provides rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy and DNA API.

Subscribe to Our Newsletters
Feedstuffs is the news source for animal agriculture

You May Also Like